Humira elbows Avastin aside in top-drug ranking

They have seen the future, and it is Humira. Market researchers EvaluatePharma have crunched the numbers on big-drug sales growth, and while their conclusions might not make Roche super-happy, they're sure to inspire high fives at Abbott Laboratories' (NYSE: ABT) headquarters: By 2016, the arthritis remedy Humira will be the world's biggest-selling drug.

Humira sales are expected to grow by 9 percent each year, so it will be raking in $10.1 billion in annual sales by 2016. According to the report, Humira will easily outsell Roche's (OTC: RHHBY) cancer drug Avastin, which had been pegged as the likely victor in the biggest-blockbuster-of-all sweepstakes. EvaluatePharma expects Avastin to reach $8.9 billion in 2016 sales.

Why the switch? As Bloomberg notes, EvaluatePharma cites "clinical setbacks" in Roche's bid to broaden Avastin use. The drug recently failed a couple of clinical trials meant to support new indications in prostate cancer and stomach cancer. However, it did perform well in a test against ovarian cancer. The company has said it's continuing its drive for additional indications; other Avastin trials are ongoing.

Rounding out the top five in EvaluatePharma's calculations are Pfizer (NYSE: PFE) and Amgen's (NASDAQ: AMGN) Enbrel, an anti-inflammatory expected to reach $7.3 billion in sales by 2016; Roche's cancer drug Rituxan, with a 3 percent compound growth rate and $6.8 billion in 2016 sales; and AstraZeneca's (NYSE: AZN) statin drug Crestor, with 4 percent CAGR and $6.3 billion in 2016 revenue. See the ranking for more.

- check out EvaluatePharma's ranking
- read the Bloomberg story (sub. req)
- see EvaluatePharma's release for more

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.